SCHEMBL4871473

SCHEMBL4871473

N#Cc1ccc(Oc2cc(Cl)ccc2N)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.56
SLC6A3 Q01959 3/20 0.56
KCNH2 Q12809 1/20 0.56
AR P10275 2/20 0.55
MRGPRX4 Q96LA9 1/20 0.45
HPGD P15428 3/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
SLC6A2 P23975 2/20 0.42
NR1I2 O75469 1/20 0.42
TTR P02766 1/20 0.42
PGR P06401 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
HSPA5 P11021 1/20 0.42
CBR1 P16152 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9658647 0.94 SLC6A3 (0.59) SLC6A4SLC6A3KCNH2ARMRGPRX4
SCHEMBL4965689 0.84 TTR (0.58) SLC6A4SLC6A3HPGDGAAALDH1A1
SCHEMBL694211 0.82 SLC6A4 (0.49) SLC6A4SLC6A3KCNH2ARMRGPRX4
SCHEMBL3365482 0.77 TTR (0.70) SLC6A4SLC6A3KCNH2ARMRGPRX4
SCHEMBL4875968 0.76 ALDH1A1 (0.49) SLC6A4SLC6A3HPGDGAAALDH1A1
SCHEMBL3365226 0.76 SLC6A4 (0.64) SLC6A4SLC6A3KCNH2ARMRGPRX4
SCHEMBL14334473 0.75 AR (0.54) SLC6A4SLC6A3KCNH2ARHPGD
SCHEMBL7668913 0.75 CYP3A4 (0.52) SLC6A3HPGDGAAALDH1A1POLB
SCHEMBL11649803 0.74 SLC6A4 (0.57) SLC6A4SLC6A3KCNH2ARMRGPRX4
SCHEMBL77027 0.74 CYP3A4 (0.50) ARHPGDGAAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
CN-102557971-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-07-11 CN disclosed
CN-101014564-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-05-09 CN disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
CN-101014564-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB (SE) 2007-08-08 CN disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 SLC6A4 1675/4885SLC6A3 3251/4885KCNH2 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.